Synthesis, anticancer evaluation, molecular docking and ADME study of novel pyrido[4ʹ,3ʹ:3,4]pyrazolo[1,5-a]pyrimidines as potential tropomyosin receptor kinase A (TrKA) inhibitors

被引：0
作者：
Nadia Hanafy Metwally
Emad Abdullah Deeb
Ibrahim Walid Hasani
机构：
[1] Cairo University,Chemistry Department, Faculty of Science
来源：
BMC Chemistry | / 18卷
关键词：
Pyrido[4ʹ,3ʹ:3,4]pyrazolo[1,5-; ]pyrimidines; Anticancer activity; TrKA enzyme; Apoptotic activity; Molecular docking; ADME studies;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The starting compound 3-amino-1,7-dihydro-4H-pyrazolo[4,3-c]pyridine-4,6(5H)-dione (1) is reacted with each of diketone and β-ketoester, forming pyridopyrazolo[1,5-a]pyrimidines 4a,b and 14a,b, respectively. The compounds 4 and 14 reacted with each of aromatic aldehyde and arenediazonium salt to give the respective arylidenes and arylhydrazo derivatives, respectively. The structure of the new products was established using spectroscopic techniques. The cytotoxic activity of selected targets was tested in vitro against three cancer cell lines MCF7, HepG2 and HCT116. The data obtained from enzymatic assays of TrKA indicated that compounds 7b and 16c have the strongest inhibitory effects on TrKA with IC50 = 0.064 ± 0.0037 μg/ml and IC50 = 0.047 ± 0.0027 μg/ml, respectively, compared to the standard drug Larotrectinib with IC50 = 0.034 ± 0.0021 μg/ml for the HepG2 cancer cell line. In cell cycle analysis, compounds 7b, 15b, 16a and 16c caused the greatest arrest in cell cycle at the G2/M phase. In addition, compound 15b has a higher apoptosis-inducing effect (36.72%) than compounds 7b (34.70%), 16a (21.14) and 16c (26.54%). Compounds 7b, 16a and 16c were shown fit tightly into the active site of the TrKA kinase crystal structure (PDB: 5H3Q). Also, ADME study was performed on some selected potent anticancer compounds described in this study.
引用
收藏
相关论文
共 218 条
[11]  
Tan J(2015)TRKing down an old oncogene in a new era of targeted therapy Cancer Discov 5 25-795
[12]  
Yamaguchi K(2019)Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence Onco Targets and Therapy 12 3171-1848
[13]  
Shi Y(2011)The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling Annu Rev Biochem 80 769-1594
[14]  
Yu P(2010)Synthesis and antimicrobial of new anthraquinone derivatives incorporating pyrazole moiety Eur J Med Chem 45 1843-3523
[15]  
Qian F(2005)Pyrazolo[1,5- Bioorg Med Chem Lett 15 1591-1113
[16]  
Chu F(2009)]pyrimidin-7-yl phenyl amides as novel antiproliferative agents: Exploration of core and headpiece structure–activity relationships Eur J Med Chem 44 3519-208
[17]  
Bentzien F(2015)Synthesis and antitumor activities of some new pyridines and pyrazolo[1,5- J Chem 39 1102-503
[18]  
Cancilla B(2010)]pyrimidines ACS Med Chem Lett 1 204-1089
[19]  
Orf J(2015)Synthesis and in vitro cytotoxic activity of novel pyrazolo[1,5-a]pyrimidines and related Schiff bases Turk Pharm Bull 63 495-214
[20]  
You A(2016)Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases Chem Intermed 42 1071-2682
12345678910